Generali Asset Management SPA SGR Acquires New Stake in Humana Inc. (NYSE:HUM)

Generali Asset Management SPA SGR acquired a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,679 shares of the insurance provider's stock, valued at approximately $1,948,000.

Other hedge funds have also bought and sold shares of the company. FPC Investment Advisory Inc. bought a new position in Humana in the fourth quarter valued at $27,000. Centricity Wealth Management LLC purchased a new position in shares of Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its position in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana in the 4th quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. boosted its stake in shares of Humana by 64.5% in the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Up 2.1 %

NYSE:HUM traded up $5.48 during mid-day trading on Monday, hitting $271.65. 1,252,836 shares of the company's stock were exchanged, compared to its average volume of 1,714,263. The company has a market cap of $32.79 billion, a PE ratio of 27.30, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The business has a fifty day moving average price of $271.33 and a 200 day moving average price of $276.25.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.30%. Humana's dividend payout ratio is 35.58%.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company's stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.37% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Morgan Stanley cut their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Barclays increased their target price on Humana from $255.00 to $270.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial increased their price objective on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Eighteen research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.